Bank of Montreal
RXRX icon

Bank of Montreal’s Recursion Pharmaceuticals RXRX Stock Holding History

Bank of Montreal’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.4K Buy
22,443
+1,292
+6% +$4.3K ﹤0.01% 3289
2026
Q1 		$64.9K Sell
21,151
-6,631
-24% -$25.6K ﹤0.01% 3235
2025
Q4 		$114K Buy
27,782
+7,195
+35% +$35.6K ﹤0.01% 3014
2025
Q3 		$100K Buy
20,587
+4,869
+31% +$25.6K ﹤0.01% 2968
2025
Q2 		$79.5K Buy
15,718
+3,881
+33% +$19.1K ﹤0.01% 3044
2025
Q1 		$62.6K Buy
11,837
+252
+2% +$1.84K ﹤0.01% 3026
2024
Q4 		$78.3K Buy
+11,585
New +$77.9K ﹤0.01% 3009
2024
Q2 		– Sell
-10,333
Closed -$124K – 4190
2024
Q1 		$124K Buy
+10,333
New +$115K ﹤0.01% 3233
2023
Q4 		– Sell
-10,810
Closed -$93K – 4260
2023
Q3 		$93K Buy
+10,810
New +$108K ﹤0.01% 3300

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of Montreal's RXRX Position: Q2 2026 in Review

Bank of Montreal increased its Recursion Pharmaceuticals (RXRX) stake by 6.1% in Q2 2026, buying an estimated $4.3K and bringing the position to 22,443 shares worth $82.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3289.

Bank of Montreal first reported a position in RXRX in Q3 2023 and has held it in 9 quarters since. The position peaked at $124K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Bank of Montreal held 22,443 shares of Recursion Pharmaceuticals worth $82.4K as of Q2 2026.
  • Bank of Montreal bought 1,292 Recursion Pharmaceuticals shares in Q2 2026, an estimated $4.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #3289 holding.
  • Bank of Montreal first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • Bank of Montreal's Recursion Pharmaceuticals position peaked at $124K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.